Arctic Bioscience AS
OSE:ABS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lululemon Athletica Inc
NASDAQ:LULU
|
CA |
Arctic Bioscience AS
Accounts Payable
Arctic Bioscience AS
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Arctic Bioscience AS
OSE:ABS
|
Accounts Payable
kr19m
|
CAGR 3-Years
31%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Accounts Payable
kr5m
|
CAGR 3-Years
50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Accounts Payable
kr5m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-10%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Accounts Payable
$4.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Accounts Payable
kr5.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Accounts Payable
kr14.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
9%
|
|
Arctic Bioscience AS
Glance View
Arctic Bioscience AS engages in the development, manufacturing, and marketing of marine ingredients extracted from herring roe. The company is headquartered in Orsta, More Og Romsdal. The company went IPO on 2021-02-24. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The firm is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The firm's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.
See Also
What is Arctic Bioscience AS's Accounts Payable?
Accounts Payable
19m
NOK
Based on the financial report for Dec 31, 2024, Arctic Bioscience AS's Accounts Payable amounts to 19m NOK.
What is Arctic Bioscience AS's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
24%
Over the last year, the Accounts Payable growth was 3%. The average annual Accounts Payable growth rates for Arctic Bioscience AS have been 31% over the past three years , 24% over the past five years .
